Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Total Current Liabilities (2021 - 2025)

Historic Total Current Liabilities for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $50.9 million.

  • ARS Pharmaceuticals' Total Current Liabilities rose 20606.39% to $50.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.9 million, marking a year-over-year increase of 20606.39%. This contributed to the annual value of $23.4 million for FY2024, which is 88034.3% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Total Current Liabilities of $50.9 million as of Q3 2025, which was up 20606.39% from $45.6 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Total Current Liabilities ranged from a high of $50.9 million in Q3 2025 and a low of $2.4 million during Q4 2023
  • Over the past 5 years, ARS Pharmaceuticals' median Total Current Liabilities value was $11.2 million (recorded in 2023), while the average stood at $15.5 million.
  • As far as peak fluctuations go, ARS Pharmaceuticals' Total Current Liabilities plummeted by 7400.14% in 2022, and later surged by 88034.3% in 2024.
  • Over the past 5 years, ARS Pharmaceuticals' Total Current Liabilities (Quarter) stood at $8.2 million in 2021, then tumbled by 33.5% to $5.4 million in 2022, then crashed by 56.08% to $2.4 million in 2023, then skyrocketed by 880.34% to $23.4 million in 2024, then surged by 117.05% to $50.9 million in 2025.
  • Its Total Current Liabilities stands at $50.9 million for Q3 2025, versus $45.6 million for Q2 2025 and $27.6 million for Q1 2025.